{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023344","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2026-05-15T12:00:31+00:00","discovered_at":"2026-05-15T12:05:00.218088+00:00","generated_at":"2026-05-15T12:06:28.479496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left","bullets":["Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).","Cash and equivalents fell to $1.5M from $8.5M at Dec 2025; company needs to raise additional capital.","R&D expenses dropped 82% to $0.5M due to Phase 1 clinical cost decrease and headcount reductions.","Executive management transition underway; reassessing development priorities and Decoy platform.","Preferred stock conversion completed during Q1 2026; all Series AA and AAA shares converted to common."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023344","json":"https://secwatch.observer/filing/0001493152-26-023344.json","markdown":"https://secwatch.observer/filing/0001493152-26-023344.md","text":"https://secwatch.observer/filing/0001493152-26-023344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/0001493152-26-023344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:06:28.479496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}